Clinical trials: Apixaban
Ischemic Stroke, Stroke, Acute
Monitoring of NOAC Therapy: Standardizing Reference Intervals
This study is aimed to establish reference intervals of NOAC (dabigatran, apixaban and rivaroxaban) in ethnic Chinese patients.
- Conditions
- Ischemic Stroke, Stroke, Acute, Stroke Syndrome, Ischemic
- Trial name
- NCT04611893
- Where
- Hong Kong
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Atrial Fibrillation
Replication of the ARISTOTLE Anticoagulant Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT04593030
- Testing
- Warfarin, Apixaban
- Where
- United States
- Volunteers
- 220,518 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia
Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking oral anticoagulant medications (apixaban, edoxaban, or rivaroxaban) for an approved indication (stroke…
- Conditions
- Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Bloodstream Infection
- Trial name
- DABI-SNAP (NCT06650501)
- Testing
- Dabigatran, Apixaban, edoxaban
- Where
- 3 sites in Canada
- Volunteers
- 300 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Atrial Fibrillation
Relationship Between Renal Function and Pharmacokinetics of Apixaban and Clinical Outcome of Apixaban in Thai Non-valvular Atrial Fibrillation Patients
The purpose of this study is to assess pharmacokinetics and pharmacodynamics of Apixaban and clinical outcome of Apixaban in Thai patients with nonvalvular atrial fibrillation with varying degree of creatinine clearance
- Trial name
- NCT04684732
- Where
- Thailand
- Volunteers
- 241 people
- Sponsor
- Chulalongkorn University
Anticoagulant-induced Bleeding, Dental Diseases
Intra- and Post- Operative Bleeding After Simple Dental Extraction in Direct Oral Anticoagulant Therapy
Direct Oral Anticoagulants were recently approved for medical treatment of several condition such as, non valvular atrial fibrillation, deep venous thrombosis, and others, substituting sometimes the conventional oral…
- Trial name
- NOADB (NCT03124030)
- Testing
- simple dental extraction
- Where
- Italy
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- University of Trieste
Pancreas Cancer, DVT
Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy
Study investigators will examine the absorption characteristics of apixaban, a direct-acting oral anticoagulation, in patients who have underwent a particular kind of surgery (pancreaticoduodenectomy) which involves resection of…
- Conditions
- Pancreas Cancer, DVT, Pulmonary Embolism
- Trial name
- PAP-UP (NCT04191928)
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Thomas Jefferson University
Vaso-occlusive Crisis, Reduction in Hospitalizations
Apixaban in Patients With Sickle Cell Disease
In patients with SCD, the use of low dose anticoagulation as an outpatient may lead to a significant decrease in morbidity and as a result, decrease healthcare utilization and costs.
- Conditions
- Vaso-occlusive Crisis, Reduction in Hospitalizations, Sickle Cell Disease
- Trial name
- NCT02179177
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Nirmish Shah
Anticoagulant-induced Bleeding
DOAC Versus VKA After Cardiac Surgery
Postoperative management of oral anticoagulation is a frequent preoccupation in cardiac surgery, concerning about half of patients.
- Trial name
- DOAC/VKA (NCT04002011)
- Testing
- Warfarin, Dabigatran, Rivaroxaban
- Sponsor
- Laval University
Atrial Fibrillation
Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S
The overall objective of this proposal is to execute a real-world database analysis to evaluate hospital readmissions among hospitalized nonvalvular atrial fibrillation (NVAF) patients in the U.S.
- Trial name
- NCT02769078
- Testing
- dabigatran, rivaroxaban, apixaban
- Volunteers
- 14,201 people
- Sponsor
- Bristol-Myers Squibb
Chronic Renal Insufficiency, Peritoneal Dialysis
Apixaban in Subjects With Peritoneal Dialysis
The primary objective of this study is to assess the pharmacokinetics of a single oral dose of apixaban (5mg) in participants with dialysis peritoneal versus participants with normal renal function.
- Trial name
- ApiDP (NCT04006093)
- Testing
- Apixaban single dose 5mg
- Where
- France
- Volunteers
- 24 people
- Sponsor
- University Hospital, Caen
Congenital Heart Disease, Atrial Arrhythmia
Apixaban in Adults With Congenital Heart Disease and Atrial Arrhythmias: the PROTECT-AR Study
The purpose of this study is to evaluate the safety and efficacy of apixaban for the prevention of thromboembolism in adult patients with congenital heart disease (CHD) and non-valvular atrial arrhythmias (AA)
- Conditions
- Congenital Heart Disease, Atrial Arrhythmia, Thromboembolism, Anticoagulants Causing Adverse Effects in Therapeutic Use
- Trial name
- PROTECT_AR (NCT03854149)
- Where
- 4 sites in Greece
- Volunteers
- 218 people
- Sponsor
- AHEPA University Hospital
Deep Vein Thrombosis, Malignancy
Efficacy of Apixaban in Malignancy With Deep Venous Thrombosis
The aim of study was to evaluate the efficacy and safety of Apixaban in patients with acute deep venous thrombosis and active malignancy compared with weight adjusted subcutaneous (LMWH).
- Trial name
- DVT (NCT04462003)
- Testing
- Apixaban, Enoxaparin
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Beni-Suef University
Random Allocation, Intermittent Fasting
Pivotal BE Study of TAH3311 ODF vs ELIQUIS® Tablet Under Fasted Condition in Healthy Volunteers
This single-dose, open-label, randomized, four-way crossover study evaluates the pharmacokinetics, safety, and tolerability of TAH3311 5 mg in healthy volunteers under fasted and fed conditions.
- Conditions
- Random Allocation, Intermittent Fasting, Enteral Feeding
- Trial name
- NCT06689436
- Testing
- 5 mg Apixaban Oral Dissolving Film (fasting), 5 mg Apixaban Oral Dissolving Film (fed), 5 mg Apixaban Oral Tablet (US RS/RLD)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- TAHO Pharmaceuticals Ltd.
Venous Thromboembolism, Cancer
Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis
This trial seeks to evaluate a management strategy after the acute treatment duration (≥ 3 months of therapeutic anticoagulation) for patients with cancer and catheter-related upper extremity deep vein thrombosis (DVT).
- Conditions
- Venous Thromboembolism, Cancer, Upper Extremity Deep Vein Thrombosis, Catheter-Related Infections
- Trial name
- STREAM-Line (NCT06603870)
- Testing
- Anticoagulation Therapy
- Where
- 2 sites in Canada
- Volunteers
- 330 people
- Sponsor
- Ottawa Hospital Research Institute
Atrial Fibrillation
A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation
To assess the effect of two doses of Apixaban (2.5 mg BID and 5 mg BID) versus Warfarin on the composite endpoint of major and clinically relevant non-major bleeding during the treatment period.
- Trial name
- NCT00787150
- Testing
- Apixaban, Warfarin sodium
- Where
- 18 sites in Japan
- Volunteers
- 222 people
- Sponsor
- Pfizer
Covid-19
A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study
The study is designed as a randomized, controlled, multi-center open-label trial to compare standard-of-care (SOC) treatment with SOC + anakinra or SOC + tocilizumab treatment in hospitalized adult subjects who are diagnosed with…
- Trial name
- NCT04412291
- Testing
- Anakinra Prefilled Syringe, Tocilizumab Prefilled Syringe, Standard-of-care treatment
- Where
- Sweden
- Volunteers
- 120 people
- Sponsor
- Karolinska University Hospital
Atrial Fibrillation
The Safety of Non-vitamin K Oral Anticoagulants Compared to Warfarin Early After Cardiac Surgery
A small pilot study comparing different blood thinners (non-vitamin K oral anticoagulants [NOACs] and warfarin) will be conducted in people at risk for blood clots after open-heart surgery.
- Trial name
- NCT05006287
- Testing
- Non-vitamin K oral anticoagulants (NOACs), Warfarin
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- St. Paul's Hospital, Canada
Atrial Fibrillation, Stroke
Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation
Atrial fibrillation (AF) is progressively common, and increases the risk of stroke five-fold. Oral anticoagulation is the mainstay therapy; however, it increases the risk of bleeding.
- Trial name
- Occlusion-AF (NCT03642509)
- Testing
- Left atrial appendage occlusion, NOAC
- Where
- 15 sites in Denmark, Finland and 3 more
- Volunteers
- 750 people
- Sponsor
- University of Aarhus
Head Injury Other, Length of Stay
Severity Factors and Needed Observation Time at ED of Patients Wih Head Injury
We know precisely which patients and when they should have an imaging test to evaluate a Head Injury (HI). But in those patients on anticoagulant and / or antiaggregant treatment we do not know the exact incidence of early and…
- Conditions
- Head Injury Other, Length of Stay, Delayed Complications
- Trial name
- HESCTCE (NCT03970421)
- Testing
- Observation
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Hospital El Escorial
NonValvular Atrial Fibrillation
Eliquis Regulatory Post Marketing Surveillance
The primary objective of this study is to examine the safety profile of Eliquis in Korean nonvalvular atrial fibrillation patients.
- Trial name
- NCT01885598
- Testing
- Apixaban
- Where
- South Korea
- Volunteers
- 3,335 people
- Sponsor
- Bristol-Myers Squibb